Visiongain Publishes Clinical Trials Market Report 2020-2030

01 July 2020
Pharma

Visiongain has launched a new pharma report Clinical Trials Market Report 2020-2030: Forecasts by Phase (Phase I, Phase II, Phase III, Phase IV), Study Design (Interventional, Observational, Expanded Access), Indication (Autoimmune/Inflammation, Pain Management, Oncology, CNS Condition, Diabetes, Obesity, Cardiovascular, Others), and Geography (North America, Latin America, Europe, Asia Pacific, MEA).

The global clinical trials market is anticipated to grow at a lucrative CAGR of ~xyz% and anticipated to reach USD xyz billion by 2020 on account of the growing prevalence of chronic diseases, and demand from developing countries.

To access the data contained in this document please email contactus@visiongain.com

With the growing burden of rare diseases around the world, there has been a rise and advancement in the therapy development of these types of diseases. While the fact remains that over 90% of these diseases lack approval for treatment and the total number of terminal rare diseases to receive the first treatment every year remains low. The introduction of policies, regulations, and incentives dedicated to reducing the rising burden of diseases has led to the significant growth in the therapeutic development for the benefit of rare disease patients. Thus, there is a demand for clinical trials globally to reduce the growing burden of diseases by helping in the development of effective and safe new vaccines and therapies. The solutions may be helpful for non-communicable diseases like diabetes & cancer, or infectious diseases prevalent in the poorest regions of the globe. Developing nations are underestimated in research due to lack of trained researchers and commercial viability, yet it is in these poorest geographies, where research-led solutions will help in curbing the growing disease burden and help in bringing the maximum impact of soaring rates of early mortality.

North America holds the majority of market share followed by Europe and will continue to dominate in the future as a result of several research projects in the region, coupled with funding for research institutes from the government. Also, the market will continue to be driven by the existence of the target population and increased R&D investment by important business organizations. Asia Pacific region is expected to experience the highest growth in terms of CAGR over the forecast period owing to growing outsourcing activities by major companies due to low labor and favorable government scenarios. Additionally, unmet needs of patients and untapped nations in this region have been attracting investments by global players and this is expected to boost the clinical trials market growth over the forecast period.

Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations, and launching new products to strengthen their position in the global clinical trials market. Companies are also expanding their R&D, distribution, and management facilities to expand their business and to hold a competitive edge in the clinical trials market.

The comprehensive market report features companies such as AAIPHARMA SERVICES CORP., ACCELL CLINICAL RESEARCH LLC, APTIV SOLUTIONS, CHILTERN INTERNATIONAL LIMITED, Clinipace, CONGENIX, COVANCE INC., ECRON ACUNOVA LTD, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, ICON PLC, IQVIA, Laboratory Corporation of America, Novo Nordisk AS, PAREXEL International Corporation, Pfizer Inc., Pharmaceutical Product Development LLC, Sanofi, Sun Pharmaceutical Industries Ltd, Wuxi AppTec among other prominent players. Also the research study offers market estimation and forecast for the period ranging 2020-2030 for global markets such as North America, Latin America, Europe, Asia Pacific and MEA along with regional sub-markets as U.S., Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Russia, India, Japan, China, Australia, ASEAN, GCC and South Africa.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Plasma Therapy Market Report 2021-2031

The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.

26 November 2020

Read

Visiongain Publishes Precision Cancer Diagnostic Test Market Report 2021-2031

Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.

26 November 2020

Read

Visiongain Publishes Top 50 Biosimilar Drug Manufacturers 2021

Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.

25 November 2020

Read

Visiongain Publishes Advanced Therapy Medicinal Products (ATMP) Market Report 2021-2031

Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing research and development activities and rising use of ATMP therapy products in treatment areas with low or no alternative treatment options support the market growth

24 November 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever